20 Results for "

Ramos

" in MedChemExpress (MCE) Product Catalog:
Products (20)

20 Results for "Ramos" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-128943
CAS No.: 2246380-69-6
Purity:  98.49%
Research Areas:  

Cancer

MAC glucuronide phenol-linked SN-38 is a pH-susceptible lactone MAC glucuronide phenol-linked SN-38 (DNA topoisomerase I inhibitor) agent linker. MAC glucuronide phenol-linked SN-38 is cytotoxic across L540cy cells and Ramos cells with IC50 values of 113 and 67 ng/mL, respectively.Albumin-coupled MAC glucosidol-linked SN-38 shows good stability in mouse plasma .
loading...
    loading...
Cat. No.: HY-15809
CAS No.: 936563-91-6
Target:  

Btk Calcium Channel

Research Areas:  

Inflammation/Immunology

(Rac)-Ibrutinib alkyne (Compound 8) is a Btk inhibitor with an IC50 of 0.72 nM. (Rac)-Ibrutinib alkyne can effectively inhibit functions related to the B-cell receptor signaling pathway, with an IC50 of 9 nM for inhibiting Ca flux in Ramos cells. (Rac)-Ibrutinib alkyne can be used in the research of diseases such as rheumatoid arthritis .
loading...
    loading...
Cat. No.: HY-133121
CAS No.: 2408842-51-1
Purity:  ≥98.0%
Target:  

Apoptosis WDR5

Research Areas:  

Cancer

WDR5-IN-1 is a potent and selective WD repeat domain 5 (WDR5) inhibitor, with a Kd of <0.02 nM. WDR5-IN-1 inhibits MLL1 histone methyltransferase (HMT) activity with an IC50 of 2.2 nM. WDR5-IN-1 diminishes MYC recruitment at WDR5-displaced genes and exhibits potent anti-proliferative effects in CHP-134 (neuroblastoma) and Ramos (Burkitt’s lymphoma) lines .
loading...
    loading...
Cat. No.: HY-112898
CAS No.: 501666-85-9
Purity:  ≥98.0%
Target:  

ADC Payloads

Research Areas:  

Cancer

DC1Sme, a DC1 derivative, exhibits IC50 values of 22 pM, 10 pM, 32 pM and 250 pM for Ramos, Namalwa, HL60/s and COLO 205 cancer cells, respectively. DC1, an analogue of the minor groove-binding DNA alkylator CC-1065, is a ADC Cytotoxin. DC1 can be used in synthesis of antibody-drug conjugates for the targeted treatment of cancer.
loading...
    loading...
Cat. No.: HY-176071
Research Areas:  

Cancer

TEC 4 is a ByeTAC (Bypassing E-Ligase-Targeting Chimera) BRD4 degrader, with 33% BRD4 remaining at 500 nM in Ramos B-cells. TEC 4 shows toxicity for Ramos B-cells, with an IC50 of 30.5 nM. ByeTACs directly recruits a protein to the proteasome via interactions with Rpn-13 for degradation. Pink: BRD4 lignad (HY-78695); Blue: Rpn-13 ligand (HY-159808); Black: linker (HY-W008352) .
loading...
    loading...
Cat. No.: HY-135122
CAS No.: 2649727-40-0
Research Areas:  

Cancer

DC10SMe is a DNA alkylator, can be used in the synthesis of antibody-drug conjugate (ADC). DC10SMe exhibits IC50s of 15 pM, 12 pM, and 12 pM for Ramos, Namalwa, and HL60/s cancer cells, respectively .
loading...
    loading...
Cat. No.: HY-112900
CAS No.: 1354787-71-5
Target:  

ADC Payloads

Research Areas:  

Cancer

DC41SMe, a DC1 derivative, shows cytotoxicity in Ramos, Namalwa, and HL60/s cells with IC50s ranging from 18-25 pM. DC1, a simplified analogue of CC-1065, is an antibody conjugate of cytotoxic DNA alkylators for the targeted treatment of cancer .
loading...
    loading...
Cat. No.: HY-150593
CAS No.: 1812188-83-2
Target:  

IRAK

Research Areas:  

Cancer

IRAK4-IN-16 (compound 4) is a potent IRAK4 (interleukin-1 receptor associated kinase 4) inhibitor, with an IC50 of 2.5 nM. IRAK4-IN-16 shows cytotoxicity activity against OCI-LY10, TMD8, Ramos and HT cells, with IC50 values of 0.2, 0.2, 0.6, and 2.7 μM, respectively .
loading...
    loading...
Cat. No.: HY-162257
CAS No.: 3016419-52-3
Target:  

Btk

Research Areas:  

Cancer

BTK-IN-34 (compound 9h) is a selective BTK inhibitor. BTK-IN-34 shows antiproliferative activity in RAMOS cells through selective inhibition of pBTK (Tyr223) without affecting Lyn and Syk, upstream proteins in the BCR signaling pathway .
loading...
    loading...
Cat. No.: HY-136342
CAS No.: 2355185-12-3
Target:  

Others

Research Areas:  

Cancer

Antitumor agent-23 is a potent anti-cancer agent with GI50s of 38, 48, 5, 27, 80, and 28 nM for lymphoma cell line GRANTA-519, KARPAS-422, KARPAS-299, RAMOS, DAUDI, and RAJI, respectively. Antitumoral activity .
loading...
    loading...
Cat. No.: HY-162407
CAS No.: 2891500-11-9
Target:  

Btk

Research Areas:  

Cancer

I-As-1 is a potent inhibitor of Bruton’s tyrosine kinase (BTK), with the IC50 of 2.35 nM. I-As-1 shows antiproliferative activities among Ramos cells and OCI-LY10 cells with IC50s of 0.52 μM and 0.11 μM, respectively .
loading...
    loading...
Cat. No.: HY-157159
Target:  

Btk

Research Areas:  

Cancer

BTK-IN-28 (compound PID-4) is a potent BTK inhibitor with anticancer activity. BTK-IN-28 has inhibitory effects on BTK and downstream signaling cascades and selectively inhibits Burkitt lymphoma RAMOS proliferation. BTK-IN-28 has no significant cytotoxicity towards non-tumor cells .
loading...
    loading...
Cat. No.: HY-135123
CAS No.: 615538-47-1
Target:  

ADC Payloads

Research Areas:  

Cancer

DC4SMe, a phosphate proagent of cytotoxic DNA alkylator DC4, can be used in the synthesis of antibody-drug conjugate (ADC). DC4SMe exhibits IC50s of 1.9 nM, 2.9 nM, and 1.8 nM for Ramos, Namalwa, and HL60/s cancer cells, respectively. DC4SMe can be used for the targeted treatment of cancer .
loading...
    loading...
Cat. No.: HY-135124
CAS No.: 1354787-76-0
Target:  

ADC Payloads

Research Areas:  

Cancer

DC44SMe, a phosphate proagent of cytotoxic DNA alkylator DC44, can be used in the synthesis of antibody-drug conjugate (ADC). DC44SMe exhibits IC50s of 2.0 nM, 2.8 nM, and 1.9 nM for Ramos, Namalwa, and HL60/s cancer cells, respectively. DC44SMe can be used for the targeted treatment of cancer .
loading...
    loading...
Cat. No.: HY-189441
Target:  

PROTACs Btk

Research Areas:  

Cancer

ISM-PR25 is an orally active PROTAC degrader targeting BTK, with a DC50 of 0.04 nM in Ramos cells. ISM-PR25 degrades BTK protein via CRL4 CRBN E3 ligase-mediated ubiquitination. ISM-PR25 can be used for research on B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-189442
Target:  

PROTACs Btk

Research Areas:  

Cancer

ISM-PR44 is an orally active PROTAC degrader targeting BTK, with a DC50 of 0.05 nM in BTK-HiBiT Ramos cells. ISM-PR44 recruits CRBN E3 ligase to induce ubiquitination and proteasomal degradation of BTK. ISM-PR44 exhibits antiproliferative and cytotoxic activities in B-cell lymphoma cells. ISM-PR44 can be used for research on B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-187161
CAS No.: 3104023-25-5
Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

IL-4-IN-3 (Compound 15/analog 15) is a selective, reversible small-molecule IL-4 inhibitor with a Kd of 31.9 nM for IL-4. IL-4-IN-3 inhibits IL-4-induced STAT6 phosphorylation in THP-1 monocytes and Ramos B lymphocytes. IL-4-IN-3 can be used in research related to allergic inflammation, cancer, autoimmune diseases, asthma and arthritis .
loading...
    loading...
Cat. No.: HY-P72074
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: AICDA; CDA2; Activation Induced Cytidine Deaminase; ARP2; AID; HEL-S-284; Single-Stranded DNA Cytosine Deaminase; Integrated Into Burkitt'S Lymphoma Cell Line Ramos; Activation-Induced Cytidine Deaminase; Epididymis Secretory Protein Li 284; Cytidine Amin
Species:  
Mouse
Source:  
E. coli
loading...
    loading...
Cat. No.: HY-178712
CAS No.: 521064-34-6
Target:  

Apoptosis

Research Areas:  

Cancer

CT 32228 is an inhibitor of lysophosphatidic acid acyltransferase-β (LPAAT-β). CT 32228 inhibits tumor cell growth. CT 32228 exhibits IC50 values of around 0.1-0.8 μM in various leukemia cell lines. CT 32228 induces caspase activation in DHL-4 and Ramos cells. CT 32228 induces apoptosis when combined with Rituximab (HY-P9913). CT 32228 results in a 50% xenograft growth delay in vivo. CT 32228 can be studied in research on acute leukemia .
loading...
    loading...
Cat. No.: HY-181996
Target:  

Btk Caspase Apoptosis PARP

Research Areas:  

Cancer

BTK-IN-47 (Compound 9e) is a covalent, selective BTK inhibitor with an IC50 of 5.15 nM against BTK. BTK-IN-47 inhibits the BTK signaling pathway, induces cell cycle arrest, and activates the canonical Caspase-dependent Apoptotic pathway (promoting the cleavage of Caspase-3, Caspase-7 and PARP), without inducing necroptosis, pyroptosis or ferroptosis. BTK-IN-47 exerts dose-dependent antiproliferative activity against hematologic tumor cell lines. BTK-IN-47 exhibits dose-dependent in vivo antitumor activity in a Ramos cell xenograft model in BALB/c nude mice. BTK-IN-47 can be used for the research of hematologic malignancies .
loading...
    loading...
  • 1